scholarly journals Anticoagulation and Bleeding: A Pooled Analysis of Lung Cancer Trials of the NCIC Clinical Trials Group

2009 ◽  
Vol 4 (5) ◽  
pp. 586-594 ◽  
Author(s):  
Aurélie Le Maître ◽  
Keyue Ding ◽  
Frances A. Shepherd ◽  
Natasha Leighl ◽  
Andrew Arnold ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Pooled Analysis ◽  
Cancer Trials

Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 8065-8065
Author(s):  
A. Le Maître ◽  
K. Ding ◽  
F. A. Shepherd ◽  
N. B. Leighl ◽  
A. Arnold ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
National Cancer Institute ◽  
Pooled Analysis ◽  
Cancer Trials

Clinical Trials and Modern Advertising: The Lung Cancer Trials Flowchart

2006 ◽  
Vol 18 (5) ◽  
pp. 376-377
Author(s):  
R. Stephens ◽  
P. Hoskin
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Cancer Trials

scholarly journals Crizotinib versus alectinib for treatment of ALK-positive non-small cell lung cancer: a pooled analysis of the ALEX, ALESIA and J-ALEX clinical trials

2020 ◽  
Author(s):  
Qinghua Zeng ◽  
Xiquan Zhang ◽  
Shan He ◽  
Zhiyong Zhou ◽  
Luping Xia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Adverse Effects ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Pooled Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma ◽  
Alk Positive

Abstract Background: Crizotinib and alectinib were the two most commonly used anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive non-small cell lung cancer (NSCLC). We compared their antitumor efficacies and adverse effects based on a pooled analysis of the ALEX, ALESIA and J-ALEX clinical trials.Methods: Seven databases were searched for eligible articles. The primary endpoints included overall survival (OS), progression-free survival (PFS), central nervous system (CNS)-PFS, drug responses and adverse effects (AEs).Results: Three randomized controlled clinical trials (ALEX, ALESIA and J-ALEX) with a total of 7 articles and 697 patients were included. Compared with crizotinib, alectinib exhibited superior efficacy in PFS (HR [hazard ratio]: 0.35, [0.25-0.49], p < 0.00001), OS (HR: 0.66, [0.47-0.92], p = 0.02), CNS-PFS (HR: 0.17, [0.11-0.24], p < 0.00001), duration of response (HR: 0.31, [0.23-0.42], p < 0.00001), objective response rate (ORR) (Risk ratio [RR]: 0.87, [0.80-0.94], p = 0.0003), partial response (PR) (RR: 0.88, [0.81-0.96], p = 0.004), and grade 3-5 AEs (RR: 1.43, [1.09-1.87], p = 0.009). Additionally, the survival advantages of alectinib compared with crizotinib increased with alectinib’s prolongation of survival time. The disease control rate, complete response and total AEs were comparable between the two groups. A greater increase in constipation, nausea, diarrhea, alanine aminotransferase, vomiting, aspartate aminotransferase, peripheral edema, dysgeusia, and visual impairment as well as a greater decrease in appetite and neutrophil count were associated with the crizotinib groupConclusions: In both antitumor efficacy and safety, alectinib appears to be superior to crizotinib for the treatment of ALK-positive NSCLC.

Venous Thromboembolism and Non-Small Cell Lung Cancer: A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trials.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3995-3995
Author(s):  
Lisa Hicks ◽  
Matthew Cheung ◽  
Baktiar Hasan ◽  
Keyue Ding ◽  
Lesley Seymour ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Advanced Nsclc ◽  
Randomized Study ◽  
Pooled Analysis ◽  
Small Cell ◽  
Prior History ◽  
Small Cell Lung ◽  
History Of

Abstract Purpose: To determine the incidence of venous thromboembolism (VTE) in patients with early and advanced non-small cell lung cancer (NSCLC); to explore predictive factors for VTE occurrence during trials in these populations, and to investigate the effect of VTE on overall survival in patients with NSCLC. Patients and Methods: Data from three National Cancer Institute of Canada Clinical Trials Group trials were included in the analyses (n=1987). JBR.10 was a randomized study of post-resection adjuvant vinorelbine/cisplatin versus observation in stage IB/II NSCLC. BR.18 was a randomized study of paclitaxel/carboplatin ± the metalloproteinase inhibitor BMS-275291 in advanced NSCLC (1st line). BR.21 was a randomized study of erlotinib versus placebo in previously treated (2nd or 3rd line) NSCLC. The relationship between VTE, cancer treatment, concomitant medications, and baseline patient characteristics was explored with univariate and multivariate analysis. Cox regression analysis was performed to determine whether VTE was independently associated with survival. Each trial was analyzed separately; in addition a pooled analysis was performed with the advanced disease trials (BR.18 and BR.21). Results: The incidence of VTE was 0% in the observation arm of JBR.10 and ranged from 3% in the adjuvant chemotherapy arm of JBR.10 to 8% in BR.18. In JBR.10, VTE was independently associated with the administration of adjuvant chemotherapy (p=0.015), baseline obesity (p=.001), and low platelet count (p=.007). For patients with advanced NSCLC, VTE was significantly more common in patients receiving chemotherapy (BR.18) compared to patients receiving erlotinib or placebo (BR.21) (8% vs 2%, p< 0.0001). In BR.18, but not BR.21, VTE was associated with a prior history of VTE (p=0.001). When BR.18 and BR.21 were pooled, prior VTE remained significant. In BR.18 and BR.21, VTE was associated with shorter survival in multivariate analysis (HR=1.69, 95%CI 1.32–2.17, p<.0001); further analyses, including JBR.10, are planned to explore this finding. Conclusion: VTE is a frequent event in patients with advanced NSCLC and is associated with the administration of chemotherapy. Treatment with metalloproteinase or epidermal growth factor inhibitors does not appear to increase the risk of VTE. In early NSCLC, adjuvant chemotherapy, morbid obesity and a prior history of VTE are associated with increased risk. VTE is associated with shortened survival in patients with advanced NSCLC. Funding for this study was provided by the Canadian Cancer Society.

A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials

Cancer ◽  
2007 ◽  
Vol 109 (4) ◽  
pp. 787-795 ◽  
Author(s):  
Mashele M. Huschka ◽  
Sumithra J. Mandrekar ◽  
Paul L. Schaefer ◽  
James R. Jett ◽  
Jeff A. Sloan
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Clinical Trials ◽  
Treatment Group ◽  
Pooled Analysis ◽  
Cancer Clinical Trials ◽  
North Central ◽  
Quality Of Life Measures ◽  
Events Data

scholarly journals Current clinical trials and patent update on lung cancer: a retrospective review

2021 ◽  
pp. LMT45
Author(s):  
Harshul Batra ◽  
Shrikant Pawar ◽  
Dherya Bahl
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Data Analysis ◽  
Main Study ◽  
Phase Ii Trials ◽  
Comprehensive Description ◽  
Multicenter Studies ◽  
The Usa ◽  
Cancer Trials ◽  
Patent Filing

Several clinical trials using different interventions are currently being sponsored to combat lung cancer at its different stages. The purpose of this study was to provide a portfolio of those trials. All active, open and recruiting clinical trials registered at ClinicalTrials.gov up to March 2018 were included. Information related to 6092 registered lung cancer trials was downloaded. Phase II trials were in the majority, comprising nearly 48.7% of total clinical trials with industry the major sponsor (41.3%) followed by NIH (12.3%). Multicenter studies were the norm accounting for 47.9% and the main study location was the USA (50.9%). Common interventions were radiation (26%), surgery (22%) and EGFR inhibitors (17%). Patent information includes major patent filing office and sponsors. The data analysis provides a comprehensive description of lung cancer trials.

Sign in / Sign up

Export Citation Format

Share Document